...also is developing agonists and antagonists, gained its TLR4 programs through the 1999 acquisition of Ribi ImmunoChem Research Inc....

...licensing deals. Burris sees the sequence of acquisitions - GenQuest Inc., Anergen Inc. and then Ribi ImmunoChem Research Inc....

...2001. CRXA obtained the vaccine, which is approved in Canada, through its 1999 acquisition of Ribi ImmunoChem Research Inc....

...A (MPL) and mycobacterial cell wall. CRXA obtained the vaccine through its 1999 purchase of Ribi ImmunoChem Research Inc. BC...

...Lederle expanded access to CRXA's monophosphoryl lipid A (MPL) adjuvant under a 1993 agreement with Ribi ImmunoChem...

...Lederle expanded access to its monophosphoryl lipid A (MPL) adjuvant under a 1993 agreement with Ribi ImmunoChem...

...III products, could provide investors with a risk diversification strategy and that the acquisition of Ribi ImmunoChem Research Inc....

...CRXA completes Ribi acquisition, B3) Ribi ImmunoChem Research Inc. (RIBI), Hamilton, Mont. Business: Autoimmune/Inflammation, Cancer, Infectious diseases Resigned: Robert...

...outstanding after the acquisition. (CRXA deal, B3; RIBI management, B9) Corixa Corp. (CRXA), Seattle, Wash. Ribi ImmunoChem Research Inc....

...Londonderry, N.H.), U.S. Bioscience Inc. (UBS, West Con-shohocken, Penn.), Anergen Inc. (ANRG, Redwood City, Calif.), Ribi ImmunoChem Research Inc....
...Londonderry, N.H.), U.S. Bioscience Inc. (UBS, West Con-shohocken, Penn.), Anergen Inc. (ANRG, Redwood City, Calif.), Ribi ImmunoChem Research Inc....